These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 19657665)

  • 1. The effect of ovarian cyst aspiration on IVF treatment with GnRH.
    Firouzabadi RD; Sekhavat L; Javedani M
    Arch Gynecol Obstet; 2010 Mar; 281(3):545-9. PubMed ID: 19657665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact.
    Qublan HS; Amarin Z; Tahat YA; Smadi AZ; Kilani M
    Hum Reprod; 2006 Mar; 21(3):640-4. PubMed ID: 16253965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study on the pregnancy outcomes of in vitro fertilization-embryo transfer between long-acting gonadotropin-releasing hormone agonist combined with transvaginal ultrasound-guided cyst aspiration and long-acting gonadotropin-releasing hormone agonist alone.
    Guo YH; Lu N; Zhang Y; Su YC; Wang Y; Zhang YL; Sun YP
    Contemp Clin Trials; 2012 Nov; 33(6):1206-10. PubMed ID: 22820320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of prestimulation ovarian cysts during assisted reproductive treatments: impact of aspiration on the outcome.
    Kumbak B; Kahraman S
    Arch Gynecol Obstet; 2009 Jun; 279(6):875-80. PubMed ID: 19023582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryopreserved blastocyst transfer: impact of gonadotropin-releasing hormone agonist versus antagonist in the previous oocyte retrieval cycles.
    Lee JR; Choi YS; Jee BC; Ku SY; Suh CS; Kim KC; Lee WD; Kim SH
    Fertil Steril; 2007 Nov; 88(5):1344-9. PubMed ID: 17548083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study.
    Schachter M; Friedler S; Ron-El R; Zimmerman AL; Strassburger D; Bern O; Raziel A
    Fertil Steril; 2008 Oct; 90(4):1087-93. PubMed ID: 18023439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of GnRH-antagonist to IVF-ET for patients with poor ovarian response].
    Wang B; Sun HX; Hu YL; Chen H; Zhang NY
    Zhonghua Nan Ke Xue; 2008 May; 14(5):423-6. PubMed ID: 18572861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro fertilization in normoresponder patients with endometriomas: comparison with basal simple ovarian cysts.
    Kumbak B; Kahraman S; Karlikaya G; Lacin S; Guney A
    Gynecol Obstet Invest; 2008; 65(3):212-6. PubMed ID: 18073487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of both serious and minor complications in young women undergoing oocyte donation.
    Maxwell KN; Cholst IN; Rosenwaks Z
    Fertil Steril; 2008 Dec; 90(6):2165-71. PubMed ID: 18249368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyst aspiration or GnRH antagonist administration for ovarian cysts detected at the start of fresh in vitro fertilization cycles.
    Pereira N; Amrane S; Hobeika E; Lekovich JP; Chung PH; Rosenwaks Z
    Gynecol Endocrinol; 2016 Jul; 32(7):562-5. PubMed ID: 26850271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
    Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years.
    D'Amato G; Caroppo E; Pasquadibisceglie A; Carone D; Vitti A; Vizziello GM
    Fertil Steril; 2004 Jun; 81(6):1572-7. PubMed ID: 15193479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.
    De Placido G; Alviggi C; Perino A; Strina I; Lisi F; Fasolino A; De Palo R; Ranieri A; Colacurci N; Mollo A;
    Hum Reprod; 2005 Feb; 20(2):390-6. PubMed ID: 15576390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting.
    Ho Yuen B; Nguyen TA; Cheung AP; Leung PC
    Fertil Steril; 2009 Aug; 92(2):499-507. PubMed ID: 18706551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Previous cycle cancellation due to poor follicular development as a predictor of ovarian response in cycles stimulated with gonadotrophin-releasing hormone agonist-gonadotrophin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Carmona F; Casamitjana R; Vanrell JA; Balasch J
    Hum Reprod; 2005 Mar; 20(3):622-8. PubMed ID: 15608035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.